Harish Pimplaskar is Aspargo’s Senior Vice President of Chemistry, Manufacturing and Controls (CMC).  Mr. Pimplaskar brings to Aspargo more than 30 years of experience in pharmaceutical development, clinical manufacturing, technology transfer, regulatory submissions, CDMO oversight, and NDA filings.   

Mr. Pimplaskar comes to Aspargo from Milestone Pharmaceuticals Inc. (Nasdaq: MIST), where he served as Vice President, CMC from 2018 to 2024. He oversaw all aspects of CMC activities for the company’s lead candidate etripamil, a drug-device combination product, and played an instrumental role in submitting its NDA in 2024. During his tenure at Milestone, Mr. Pimplaskar provided leadership in product development, manufacturing, and regulatory submissions.   

Prior to Milestone, Mr. Pimplaskar was Executive Director, CMC and Pharmaceutical development at Axsome Therapeutics (Nasdaq: AXSM) from 2015 to 2018, where he led various research and development programs through IND and IMPD submissions in CNS indications. Before joining Axsome, Mr. Pimplaskar led the CMC efforts of Chelsea Therapeutics (Nasdaq: CHTP)  (now Lundbeck) from 2008 to 2014 for the company’s NDA filing for Northera, a drug for the treatment of Neurogenic Orthostatic Hypotension, an orphan designation. The FDA approved Nothera in 2014.  

In his early career, Mr. Pimplaskar has served progressively senior positions in the area of research and development and manufacturing at Upsher-Smith Laboratories (now Bora Pharmaceuticals), Pfizer Consumer Health (NYSE: PFE) and MDRNA inc. Mr. Pimplaskar has authored numerous publications and holds multiple patents in the area of solids, liquids and nasal drug delivery. He is an active member of the American Association of Pharmaceutical Scientists (AAPS) and the American Chemical Society.   

Mr. Pimplaskar holds a Bachelor of Pharmacy (B. Pharm.) degree from University of Pune, M.S. in Pharmaceutics from the University of Rhode Island, and an MBA from Averett University, VA.